Selecta Biosciences downgraded by SVB Securities with a new price target
$SELB
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/18/2023 | $1.00 | Outperform → Market Perform | SVB Securities |
| 6/14/2022 | $6.00 → $5.00 | Buy | Needham |
| 6/6/2022 | $7.00 | Outperform | SVB Leerink |
| 11/1/2021 | $6.00 → $7.00 | Buy | Needham |
DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)